Literature DB >> 12399976

A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript.

T Imamura1, A Morimoto, S Ikushima, N Kakazu, S Hada, Y Tabata, T Yagi, T Inaba, S Hibi, T Sugimoto, S Imashuku.   

Abstract

Infant acute lymphoblastic leukemia (ALL) is characterized by the presence of the proB phenotype (CD10(-)/CD19(+)), poor prognosis and frequent rearrangement of the mixed lineage leukemia (MLL) gene. The most frequent rearrangement is t(4;11)(q21;q23), the role of whose product, the MLL-AF4 fusion transcript, has been extensively studied in leukemogenesis. In a cell line of infant leukemia with MLL rearrangement denoted KP-L-RY, panhandle PCR amplification of cDNA revealed the presence of a fusion transcript, MLL-AF5q31, indicating that AF5q31 is also a partner gene of MLL. In this fusion transcript the MLL exon 6 is fused in frame to the 5' side of the putative transactivation domain of AF5q31. The AF5q31 protein is a member of the AF4/LAF4/FMR2-related family of proteins, which have been suggested to play a role in hematopoietic cell growth and differentiation. The MLL-AF5q31 fusion transcript, although probably rare, appears to be associated with the pathogenesis of infant ALL like MLL-AF4. Co-expression of HoxA9 and Meis1 genes in the KP-L-RY cell line indicated possible functional similarity between MLL-AF4 and MLL-AF5q31. Further understanding of the function of AF5q31 as well as the specific leukemogenic mechanism of MLL-AF5q31 awaits future studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399976     DOI: 10.1038/sj.leu.2402665

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells.

Authors:  Carl E Allen; Jianguo Du; Bo Jiang; Qin Huang; Adam J Yakovich; John A Barnard
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

2.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.

Authors:  Piu Wong; Masayuki Iwasaki; Tim C P Somervaille; Chi Wai Eric So; Chai Wai Eric So; Michael L Cleary
Journal:  Genes Dev       Date:  2007-10-17       Impact factor: 11.361

3.  MCEF is localized to the nucleus by protein sequences encoded within three distinct exons, where it represses HIV-1 Tat-transactivation of LTR-directed transcription.

Authors:  Maksymilian F Niedzielski; Robert Hopewell; Zohra Ismail; Mario C Estable
Journal:  Int J Biol Sci       Date:  2007-03-01       Impact factor: 6.580

4.  AFF3 upregulation mediates tamoxifen resistance in breast cancers.

Authors:  Yawei Shi; Yang Zhao; Yunjian Zhang; NiJiati AiErken; Nan Shao; Runyi Ye; Ying Lin; Shenming Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-10-16

5.  Meis1 Regulates Nociceptor Development and Behavioral Response to Tactile Stimuli.

Authors:  Zheng Cao; Chengcheng Huang; Fumin Lu; Xuequan Jiang; Yong Hu; Cheng Cao; Zijing Liu
Journal:  Front Mol Neurosci       Date:  2022-07-06       Impact factor: 6.261

6.  CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.

Authors:  Klaartje Somers; Daria A Chudakova; Shiloh M C Middlemiss; Victoria W Wen; Molly Clifton; Alan Kwek; Bing Liu; Chelsea Mayoh; Angelika Bongers; Mawar Karsa; Sukey Pan; Sarah Cruikshank; Marissa Scandlyn; Wendi Hoang; Toshihiko Imamura; Ursula R Kees; Andrei V Gudkov; Olga B Chernova; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  Oncotarget       Date:  2016-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.